
Cardiawave Announces Positive 12-Month Results from Its “Valvosoft® FIM Study” and “Valvosoft® Pivotal Study” for the Treatment of Severe Symptomatic Aortic Stenosis (sSAS)
Levallois-Perret, France – May 22, 2025 — Cardiawave SA, medtech company specialized in valvular heart disease, presented today at the EuroPCR Congress the 12-month results from its “Valvosoft® FIM Study”…